Abstract
A comparative study of Cefuroxime with Cefazolin for bacterial pneumonia and chronic respiratory tract infections was carried out by the double blind method. Each one of the antibiotics was given in doses of 750 mg I. V. three times daily for seven to fourteen days. 1 Cases subject to analysis: Of 201 cases recruited in this trial, 149 (Cefuroxime 72, Cefazolin 77) were adopted by Committee in evaluation on clinical efficacy and 197 (Cefuroxime 96, Cefazolin 101) were adopted by Controller after judged by doctors in charge. The background characteristics of the patients in Cefuroxime and Cefazolin treated groups were almost the same. 2. Overall clinical efficacy judged by Committee: Cefuroxime was significantly superior to Cefazolin in judgement on the 7 th day of treatment in the “excellent” rate of total cases and of moderate cases, and in the efficacy of cases with infection due to gram positive cocci, etc. Cefuroxime showed also a tendency to be superior to Cefazolin in the “excellent” rate of patients with pneumonia, the efficacy rate of moderate cases and in the clinical efficacy in chronic respiratory tract infections, etc. 3. Overall clinical efficacy judged by doctors in charge: As for the overall clinical efficacy in total cases, there was no significant difference between Cefuroixme and Cefazolin in both judgements on the 7 th day of treatment and at the end of treatment. 4. Improvement of clinical findings: As for the degree of improvement in chest X-ray findings on the 14 th day of treatment compared with the initial ones, Cefuroxime was significantly superior to Cefazolin in cases adopted by Committee and showed a tendency to be superior to Cefazolin in cases adopted by Controller. Besides, Cefazolin showed a tendency to be better than Cefuroxime in property and volume (only cases adopted by Committee) of sputum in the judgement after three days treatment. 5. Bacteriological response classified by clinical isolates from sputum: Cefuroxime showed a tendency to eradicate Heamophilus at a higher rate than Cefazolin. 6. Side effects and abnormal laboratory findings due to the medication: As for the incidence of side effects including abnormal laboratory findings, there was no significant difference between Cefuroxime and Cefazolin in both judgements by Committee (186 cases) and those by doctors in charge (197 cases). 7. Clinical usefulness judged by doctors in charge: Cefuroxime showed a tendency to be superior to Cefazolin in usefulness rate (judged as useful or slightly useful). From the results obtained, it has been concluded that Cefuroxime is a useful antibiotic for treatment of bacterial pneumonia and chronic respiratory tract infections.
Original language | English |
---|---|
Pages (from-to) | 687-714 |
Number of pages | 28 |
Journal | Chemotherapy |
Volume | 28 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1980 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology